Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Clinical Trial 39769

Winter Haven, FL 33880

Study Summary:

This is a research study of an investigational drug called PB-119.  Type 2 diabetes mellitus (T2DM) accounts for 90% to 95% of all diabetes, and is characterized by a decrease in insulin secretion, insulin resistance, and an increase in blood glucose due to increased glucose production in the liver.  Diet control and physical exercise are the main methods for the treatment of T2DM patients with a slight increase in fasting blood glucose. If the diet and exercise therapy does not adequately reduce blood sugar, T2DM medications are given.    

One medication for T2DM is exenatide (Byetta®, Bydureon®) Exenatide is in a class of drugs called incretin mimetics because these drugs mimic the effects of incretins. Incretins, such as human-glucagon-like peptide-1 (GLP-1), are hormones that are produced and released into the blood by the intestine in response to food. GLP-1 increases the secretion of insulin from the pancreas, slows absorption of glucose from the gut, and reduces the action of glucagon (a hormone that increases glucose production by the liver). All three of these actions reduce levels of glucose in the blood. In addition, GLP-1 reduces appetite. Exenatide is a synthetic (manmade) hormone that resembles and acts like GLP-1.  The efficacy and safety of exenatide has been well validated in a wide range of clinical applications and will benefit patients with T2DM. In spite of this, because of the short half-life and the need for frequent injections, patient compliance is anticipated to be the major disadvantage of GLP-1 analogue when competing with DPP-4 inhibitors in the market.  

The sponsor has modified exenatide by PEGylation technology.  PEGylation is the process of attaching the strands of the polymer PEG to molecules. The PEGylated exanatide is not removed as quickly from the blood and the dosing frequency can be reduced to once weekly. In addition, PEGylation can modify the protein surface, changing the immunogenicity, so as to achieve a reduction in immune adverse reactions.  

The purpose of this research study is to compare the effects (both good and bad) and tolerability of PB-119 in research participants with T2DM, not well controlled by Metformin monotherapy. This study will also evaluate how much drug gets into the body and what the body does to the drug (pharmacokinetics or PK). The study drug will be compared to a placebo. 

Qualified Participants Must:

• Be at least 18 years of age
• Have been diagnosed with Diabetes Type II for at least 3 months and have been stable on their current Metformin dose for at least 8 weeks
• Be willing to receive a subcutanous injection (subcutanous injections go right underneath the skin, they do not go down into the muscle)
• Not have taken any other diabetic medications within the last 3 months

Qualified Participants May Receive:

- Medication and injection being administered by study site staff

- Compensation for time and travel expenses

- Physicals with a board certified physicians

- Labratory blood work

Research Site Profile

View Clinic Profile

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.